Clinical trial · Interventional
Application Circulating Tumor DNA Dynamic Monitoring in Clinical Treatment of Metastatic Renal Cell Carcinoma
A Prospective Observational Study of Molecular Classification and Circulating Tumor DNA Dynamic Monitoring to Explore Related Factors That Predict the Efficacy of Single Targeted Therapy or Combined With Immunotherapy for Metastatic Renal Cell Carcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Next-Generation Sequencing and whole transcriptome RNA sequencing were used to detect genomic variation and expression in tissues or blood, respectively. The treatment outcome of single targeted therapy or combined with immunotherapy was observed and followed up. Through this study, we intend to achieve RNA molecular classification of Chinese mRCC patients and to evaluate the correlation between ctDNA level, RNA molecular classification and treatment outcome, provide reference for metastatic RCC precise diagnosis and treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Renal Cell Carcinoma | Renal Cell Carcinoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| PD-1 inhibitor combined with axitinib | Drug | — | UNRESOLVED |
| sunitinib or pazopanib | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Single targeted therapy
- description
- sunitinib or pazopanib
- interventionNames
- Drug: sunitinib or pazopanib
- type
- EXPERIMENTAL
- label
- targeted therapy combined with immunotherapy
- description
- Programmed death-ligand 1 Inhibitor combined with axitinib
- interventionNames
- Drug: PD-1 inhibitor combined with axitinib
Primary outcomes (1)
- measure
- progression-free survival
- timeFrame
- From drug taken until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 20 months
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Clinically diagnosed with renal cell carcinoma confirmed by pathology, including clear renal cell carcinoma and type I papillary renal cell carcinoma, type II papillary renal cell carcinoma, chromophobe renal cell carcinoma and renal cell carcinoma with sarcomatoid differentiation, etc * Have distant metastasis * metastatic RCC * Eastern Cooperative Oncology Group 0 to 1 * No obvious abnormality was found in blood routine examination, coagulation and liver and kidney function Exclusion Criteria: * • Previously received systematic treatment * Failure to obtain baseline tumor tissue / blood samples * A history of infection with human immunodeficiency virus, or suffer from other acquired and congenital immunodeficiency diseases, or have a history of organ transplantation, or have a history of organ transplantation * A history of allergy to disease treatment drugs * During lactation or pregnancy
References
Publications (0)
Data not yet available